{"schema_version":"secwatch.filing_event.v1","accession":"0001034842-26-000016","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.432311+00:00","generated_at":"2026-05-15T21:58:50.974306+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Rigel Q4 net product sales $65.4M record; full year net income $367M, includes $245.9M tax benefit","bullets":["Q4 2025 net product sales $65.4M (+41% YoY); TAVALISSE $45.6M (+47%), GAVRETO $10.2M (+27%), REZLIDHIA $9.6M (+29%).","Full year 2025 net product sales $232M (+60% YoY); total revenue $294.3M.","Q4 net income $268.1M ($14.72 basic EPS) includes $245.9M non-cash deferred tax benefit; FY net income $367M.","2026 guidance: total revenue $275-290M, net product sales $255-265M, expects positive net income.","Cash $155.0M at Dec 31, 2025 vs $77.3M at Dec 31, 2024; R289 dose expansion enrollment on track for H2 2026 RP2D."],"urls":{"canonical":"https://secwatch.observer/filing/0001034842-26-000016","json":"https://secwatch.observer/filing/0001034842-26-000016.json","markdown":"https://secwatch.observer/filing/0001034842-26-000016.md","text":"https://secwatch.observer/filing/0001034842-26-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000016/0001034842-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000016/rigl-20260303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:58:50.974306+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}